蛋白质组学方法在加速精神疾病药物研发中的应用。

Application of Proteomic Approaches to Accelerate Drug Development for Psychiatric Disorders.

作者信息

Rahmoune Hassan, Martins-de-Souza Daniel, Guest Paul C

机构信息

Department of Chemical Engineering and Biotechnology, University of Cambridge, CB2 3RA, Cambridge, UK.

Laboratory of Neuroproteomics, Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas (UNICAMP), Rua Monteiro Lobato 255 F/01, Cidade Universitária Zeferino Vaz, 13083-862, Campinas, Brazil.

出版信息

Adv Exp Med Biol. 2017;974:69-84. doi: 10.1007/978-3-319-52479-5_4.

DOI:10.1007/978-3-319-52479-5_4

PMID:28353225

Abstract

Proteomic-based biomarkers are now an integral part of the drug development process. This chapter covers the role of proteomic biomarker tests as useful tools for improving preclinical research and clinical development. One medical area that has been lagging behind this process is the study of psychiatric disorders, and this is most likely due to the complexity of these diseases. The potential of incorporating biomarkers in the clinical pipeline to improve decision-making, accelerate drug development, improve translation and reduce development costs is also discussed, with a focus on psychiatric diseases like schizophrenia. This chapter will also discuss the next steps that must be taken to keep moving this process forwards.

摘要

基于蛋白质组学的生物标志物如今已成为药物研发过程中不可或缺的一部分。本章介绍了蛋白质组学生物标志物检测作为改善临床前研究和临床开发的有用工具所发挥的作用。在这一过程中一直滞后的一个医学领域是精神疾病研究，这很可能是由于这些疾病的复杂性所致。文中还讨论了在临床流程中纳入生物标志物以改善决策、加速药物研发、促进转化并降低研发成本的潜力，重点关注精神分裂症等精神疾病。本章还将讨论为推动这一进程向前发展必须采取的后续步骤。